Susceptibility of RSV B strains with and without prevalent nirsevimab binding site substitutions I206M + Q209R.
infections
VIRUS, INFECTIONS
F, fusion protein; ICAt the time of symptomatic illness, RSV titers were similar in participants with breakthrough infections, regardless of whether the virus had resistance-associated substitutions (Supplementary Fig. 